C.S. Group, Taiwan’s largest specialized Taiwanofungus Camphoratus retail chain, hosted the ‘Antcin A Veterinary Drug Phase I Trials & 2026 Capital Market Progress Report’ on December 6, 2025. During the briefing, the Group announced that Phase I Pharmacokinetics (PK) trials for its novel pet drug were successfully completed mid-year. The Group expects to initiate Phase II Toxicological Safety trials in the first quarter of 2026, positioning the product to become Taiwan’s first domestically developed Antcin A-based veterinary drug.
